Patents by Inventor Francois Dalencon

Francois Dalencon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20170326221
    Abstract: The invention relates to a method of detoxifying a lipopolysaccharide (LPS) or a lipid A from a Gram-negative bacterium, which comprises mixing the LPS or the lipid A with a cationic lipid so as to form a complex in which the LPS or the lipid A is associated with the cationic lipid. According to the conventional preparation modes, the cationic lipid with the co-lipid, if this latter is present, get(s) structured into complexes i.a. liposomes. When preparing lipidic complexes, the addition of LPS or Lipid A leads to an association of this latter with the cationic lipid and as a result, the LPS or lipid A is substantially detoxified. The LPS or lipid A detoxified by the complexes, e.g. when incorporated into liposomes, can be used as vaccinal antigen or as adjuvant.
    Type: Application
    Filed: August 7, 2017
    Publication date: November 16, 2017
    Applicant: Sanofi Pasteur SA
    Inventors: Jean Haensler, Francois Dalencon, Monique Moreau, Noelle Mistretta
  • Publication number: 20160367655
    Abstract: The present invention provides compositions comprising a Chlamydial major outer membrane protein (referenced herein as “MOMP”), from at least one Chlamydial serovar and an adjuvant, characterized in that the adjuvant comprises the product E6020 having CAS Number 287180-63-6. The composition may further comprise at least one carrier system (e.g., emulsion, mineral particle). The MOMP protein may be derived from any species of Chlamydia (e.g., C. trachomatis, C. pneumoniae, C. psittaci, or C. trachomatis MoPn). In preferred embodiments, the composition comprises one or more major outer membrane proteins each derived from different serovars of C. trachomatis. The invention also provides methods of inducing an immune response to a Chlamydia species (e.g., C. trachomatis) in a subject, by administering to the subject a composition of the invention.
    Type: Application
    Filed: March 21, 2016
    Publication date: December 22, 2016
    Inventors: Scott Gallichan, Ausra Mancevski, Nathalie Reveneau, Jin Su, Francois Dalencon, Jean Haensler
  • Patent number: 9327021
    Abstract: The present invention provides compositions comprising a Chlamydial major outer membrane protein (referenced herein as “MOMP”), from at least one Chlamydial serovar and an adjuvant, characterized in that the adjuvant comprises the product E6020 having CAS Number 287180-63-6. The composition may further comprise at least one carrier system (e.g., emulsion, mineral particle). The MOMP protein may be derived from any species of Chlamydia (e.g., C. trachomatis, C. pneumoniae, C. psittaci, or C. trachomatis MoPn). In preferred embodiments, the composition comprises one or more major outer membrane proteins each derived from different serovars of C. trachomatis. The invention also provides methods of inducing an immune response to a Chlamydia species (e.g., C. trachomatis) in a subject, by administering to the subject a composition of the invention.
    Type: Grant
    Filed: November 15, 2011
    Date of Patent: May 3, 2016
    Assignees: Sanofi Pasteur Limited, Sanofi Pasteur S.A.
    Inventors: Scott Gallichan, Ausra Mancevski, Nathalie Reveneau, Jin Su, Francois Dalencon, Jean Haensler
  • Publication number: 20140178478
    Abstract: The invention relates to an oil-in-water adjuvant emulsion which comprises at least: squalene, an aqueous solvent, a polyoxyethylene alkyl ether nonionic surfactant, a hydrophobic nonionic surfactant, which emulsion is thermoreversible, and wherein 90% of the population by volume of the oil drops has a size less than 200 nm. The invention also relates to a process for preparing an immunogenic composition according to which at least one vaccine antigen is mixed with an oil-in-water emulsion, wherein the oil-in-water emulsion is obtained by means of a temperature-variation phase-inversion process.
    Type: Application
    Filed: February 28, 2014
    Publication date: June 26, 2014
    Applicant: Sanofi Pasteur
    Inventors: Marie-Francoise Klucker, Francois Dalencon, Patricia Probeck-Quellec
  • Patent number: 8703095
    Abstract: The invention relates to an oil-in-water adjuvant emulsion which comprises at least: squalene, an aqueous solvent, a polyoxyethylene alkyl ether nonionic surfactant, a hydrophobic nonionic surfactant, which emulsion is thermoreversible, and wherein 90% of the population by volume of the oil drops has a size less than 200 nm. The invention also relates to a process for preparing an immunogenic composition according to which at least one vaccine antigen is mixed with an oil-in-water emulsion, wherein the oil-in-water emulsion is obtained by means of a temperature-variation phase-inversion process.
    Type: Grant
    Filed: July 7, 2006
    Date of Patent: April 22, 2014
    Assignee: Sanofi Pasteur S.A.
    Inventors: Marie-Francoise Klucker, Francois Dalencon, Patricia Probeck-Quellec
  • Publication number: 20130344109
    Abstract: The present invention provides compositions comprising a Chlamydial major outer membrane protein (referenced herein as “MOMP”), from at least one Chlamydial serovar and an adjuvant, characterized in that the adjuvant comprises the product E6020 having CAS Number 287180-63-6. The composition may further comprise at least one carrier system (e.g., emulsion, mineral particle). The MOMP protein may be derived from any species of Chlamydia (e.g., C. trachomatis, C. pneumoniae, C. psittaci, or C. trachomatis MoPn). In preferred embodiments, the composition comprises one or more major outer membrane proteins each derived from different serovars of C. trachomatis. The invention also provides methods of inducing an immune response to a Chlamydia species (e.g., C. trachomatis) in a subject, by administering to the subject a composition of the invention.
    Type: Application
    Filed: November 15, 2011
    Publication date: December 26, 2013
    Applicants: SANOFI PASTEUR, S.A., SANOFI PASTEUR LIMITED
    Inventors: Scott Gallichan, Ausra Mancevski, Nathalie Reveneau, Jin Su, Francois Dalencon, Jean Haensler
  • Publication number: 20100291192
    Abstract: The invention relates to a method of detoxifying a lipopolysaccharide (LPS) or a lipid A from a Gram-negative bacterium, which comprises mixing the LPS or the lipid A with a cationic lipid so as to form a complex in which the LPS or the lipid A is associated with the cationic lipid. According to the conventional preparation modes, the cationic lipid with the co-lipid, if this latter is present, get(s) structured into complexes i.a. liposomes. When preparing lipidic complexes, the addition of LPS or Lipid A leads to an association of this latter with the cationic lipid and as a result, the LPS or lipid A is substantially detoxified. The LPS or lipid A detoxified by the complexes, e.g. when incorporated into liposomes, can be used as vaccinal antigen or as adjuvant.
    Type: Application
    Filed: May 14, 2010
    Publication date: November 18, 2010
    Applicant: Sanofi Pasteur
    Inventors: Jean Haensler, François Dalençon, Monique Moreau, Noëlle Mistretta
  • Publication number: 20070014805
    Abstract: The invention relates to an oil-in-water adjuvant emulsion which comprises at least: squalene, an aqueous solvent, a polyoxyethylene alkyl ether nonionic surfactant, a hydrophobic nonionic surfactant, which emulsion is thermoreversible, and wherein 90% of the population by volume of the oil drops has a size less than 200 nm. The invention also relates to a process for preparing an immunogenic composition according to which at least one vaccine antigen is mixed with an oil-in-water emulsion, wherein the oil-in-water emulsion is obtained by means of a temperature-variation phase-inversion process.
    Type: Application
    Filed: July 7, 2006
    Publication date: January 18, 2007
    Applicant: Sanofi Pasteur
    Inventors: Francois Dalencon, Marie-Francoise Klucker, Patricia Probeck-Quellec
  • Publication number: 20060165717
    Abstract: The present invention involves the use of DCchol for preparing a vaccine composition intended to be administered to newborns.
    Type: Application
    Filed: January 24, 2006
    Publication date: July 27, 2006
    Inventors: Francois Dalencon, Claire-Anne Siegrist